Crane Process Flow Technologies (CPFT) has appointed Nigel Wood to the newly created position of operations manager. He will assume overall responsibility for the company's Saunders HC4 range of sanitary and aseptic diaphragm valves with a view to maximising growth opportunities.
ImClone Systems has named Michael Howerton senior vice president and chief financial officer. Since May 2003, Howerton has served as ImClone Systems' vice president, finance and business development and acting chief financial officer and prior to that, as the company's vice president, business development. Prior to joining ImClone Systems in August 2001, he built a 25-year career at Bristol-Myers Squibb in a variety of finance, planning and business development management positions.
NeoPharm Pharmaceuticals' board of directors has appointed Gregory Young as the company's new president and chief executive officer. He replaces James Hussey, who resigned as the company's president and ceo and as a member of the board of directors. Hussey is leaving NeoPharm to pursue other opportunities.
Sigma-Aldrich Corporation has announced that Dr David A. Smoller has been named vice president of r&d to help develop new and innovative products for life science and high technology research. Most recently Dr Smoller was ceo and president of Proteo-Plex, a seed stage spin-out focusing on functional genomics. In 1992, he founded Genome Systems, which provided the scientific community with access to genome project-related technologies. Dr Smoller stayed at the helm of the organisation until it was acquired in 1996 by the Incyte Corporation.
Quintiles Transnational Corporation has appointed John Ratliff as chief financial officer, succeeding James L. Bierman. Ratliff joins Quintles from Acterna, where he served as senior vice president and chief financial officer.
Penwest Pharmaceuticals has appointed Dr Alan F. Joslyn as senior vice president of research and development. He will be responsible for the company's clinical operations, regulatory affairs, pharmaceutical development and technology research. Dr Joslyn most recently served as vice president, internal medicine, at Johnson & Johnson Pharmaceutical Research & Development (J&JPRD). In this position, he was responsible for all aspects of the global development of Aciphex/Pariet and prucalopride.
Bruker Daltonics, an operating company of Bruker BioSciences Corporation, has appointed Dr Ian Sanders as its assistant vice president for European life-science sales. He will share responsibility for the management of the company's marketing, sales, applications and customer support activities in Europe, and will also join the Bruker Daltonics global management team. Dr Sanders joined Bruker Daltonics in 2000 following a 10-year career in drug discovery research for both large pharmaceutical and venture biotechnology companies. Initially responsible for the UK business, in 2002 his role expanded to manage life-science sales in the UK, Scandinavia and the Netherlands.
Albion Chemicals Group is to integrate its customer facing sales and marketing resources for its manufacturing business and expanding chemical distribution operation, to create one point of contact for customers serviced by both divisions. As part of the restructure, Clare Waters has been appointed sales and marketing director with responsibility for both distribution and bulk liquid divisions.
Dr Andre Pernet has joined Bionest Partners, a provider of advisory and management services to life science companies, as associate member focused on technology assessment and management for pharmaceutical and biotechnology companies. He was previously corporate officer and vice president, pharmaceutical products research and development with Abbott Laboratories, where he headed an organisation of 2,700 scientists. During his tenure, he developed drugs in the areas of schizophrenia, manic depression, analgesia, epilepsy, prostate hypertrophy, anti-infectives and strokes.
Don Sellers has resigned as president and ceo of SciClone after 11 years of service. He has also resigned from the board of directors, but will continue to act as a consultant to the company. The board of directors is actively working to identify a successor. In the interim, Dr Alfred Rudolph, coo, and Richard Waldron, cfo, will form an office of the president to guide the company along with the board's continuing oversight.
NJM/CLI has appointed Fred McMahon as national accounts manager - print & apply/RFID. McMahon is responsible for bringing the company's innovative labelling and RFID solutions to customers in the food, beverage, pharmaceutical and other industries in the drive to meet demands for automatic identification to achieve product tracking.
Collette, the Belgian manufacturer of granulation and drying equipment for the pharmaceutical industry, has reinforced its sales department with the appointment of a new sales manager for the North American market, David Decker. Decker has a degree in industrial engineering and has more than 14 years' experience in high shear granulation and fluid bed drying for the pharmaceutical industry, both in project design and improvement, and in project management and sales.
Keith Hopkins has been appointed to the board of directors of global speciality chemicals company Elementis. Hopkins is chairman of Scapa Group and a non executive director of British Vita. Previously, he has held the positions of group chief executive and then chairman of Croda International. Jonathan Fry, the current chairman of Elementis, will retire from the board on 7 October, 2004 and it is intended that Hopkins will assume the role of chairman from that date.
Detica, the specialist IT consultancy, has appointed Zak Doffman to head up its new life sciences division. Doffman joins from Accenture where he spent 10 years focused on the life sciences sector. Detica, which counts AstraZeneca among its existing clients, specialises in areas such as customer intelligence, security & fraud, risk & compliance management and business intelligence. Doffman believes there is a tremendous opportunity for these services within life sciences.
Jorge Nogueira has been appointed senior vice president of Rhodia Pharma Solutions' consumer health business unit. In this role, he will be responsible for growing the profitability of Rhodia's aspirin, paracetamol and salicylates chain for pharmaceutical applications, and increasing the company's presence in nutraceuticals markets. Nogueira was most recently in charge of Rhodia Pharma Solutions' sales and business development team. He has also served as the head of the company's perfumery & specialties enterprise, North American organic intermediates, and South American specialty chemicals operations.